Uncategorized
Aerie reports net loss of $22.7 million in first quarter
Aerie Pharmaceuticals reported a GAAP net loss of $22.7 million, or $0.85 per share, in the first quarter compared with a GAAP net loss of $17.2 million, or $0.70 per share, in the same quarter of 2015, according to a press release.Operating expenses were reported at $22.1 million in the first quarter, which included $12.3 million in research and development expenses and $9.8 million in general and administrative expenses.